DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "PharmaPoint: Type 2 Diabetes - Global Drug Forecast and Market Analysis to 2025" report to their offering.
The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2015 and 2025, almost doubling over this period.
The main drivers of growth will be the dramatic increase in disease prevalence and physicians' efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.
We anticipate that the type 2 diabetes market will experience a shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the glucagon-like peptide-1 receptor agonist (GLP-1RA) class and sodium-glucose co-transporter-2 inhibitor (SGLT-2I) class will occur; while dipeptidyl peptidase-4 inhibitors (DPP-4Is) will continue to grow, but at a much slower rate than previous years. GLP-1RAs and SGLT-2Is will experience the fastest growth of all classes at a CAGR of 12.2% and 13.0% respectively.
Key Findings
- The main driver of the enormous expansion of the T2D market will be the dramatic increase in disease prevalence, which is attributable to increased life expectancy and an increasingly sedentary and stressful lifestyle.
- The second largest driver will be the physicians' efforts to delay disease progression through the use of combination therapies and novel branded drugs.
- With the recent therapeutic guidelines putting emphasis on a patient-tailored approach in treating type 2 diabetes, pharmaceutical companies will achieve considerable success with their me-too drugs.
- In the future, companies will have to shift their focus towards competitive pricing, niche drugs aimed at smaller patient groups, and drugs that increase patient compliance (through more convenient administration).
- To date, no drug has demonstrated sustainable efficacy in the treatment of T2D. This unmet need presents a large opportunity for investment by drug developers.
Key Topics Covered:
1 Tables & Figures
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Competitive Assessment
7 Unmet Needs and Opportunities
8 Pipeline Assessment
9 Current and Future Players
10 Market Outlook
11 Appendix
Companies Mentioned
- Eli Lilly
- Novo Nordisk
- Sanofi
- GlaxoSmithKline
- AstraZeneca
- Merck & Co.
- Boehringer Ingelheim
- Takeda
- Roche
- Pfizer
- Johnson & Johnson
- Novartis
- Intarcia Therapeutics
For more information about this report visit http://www.researchandmarkets.com/research/9qmfk9/pharmapoint_type
